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Introduction
Cognitive impairment (CI) is frequent in Parkinson’s 
disease (PD) even in early stages and over 75% of PD pa-
tients may develop dementia over time [1]. The combina-
tion of Lewy pathology and amyloid pathologies is the most 
robust pathological substrate of PD dementia [2].  Cognitive 
impairment has been found to be associated with multiple 
neurotransmitter transmission deficiencies, including do-
pamine and acetylcholine, indicating a widespread neu-
rotransmitter dysfunction in PD-related dementia [3], but 
cholinergic deficits due to degeneration of the nucleus basa-
lis of Meynert have been the most involved in this process 
[4]. Cognitively impaired patients have particular clinical 
features – older age, postural instability-gait disorder phe-
notype, psychiatric symptoms (psychosis, hallucinations, 
and depression), sleep disorders, rapid eye movement 
(REM) sleep behavior disorder, and diurnal sleepiness); 
all these factors have been associated with PD cognitive 
worsening [5]. PD patients with comorbid cardiovascular 
disorders have an extra risk of developing gait and balance 
disorders and dementia [5]. A study has shown that PD pa-
tients with concurrent cerebral microangiopathy fall more 
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Abstract
Background: Cognitive impairment (CI) is frequent in Parkinson’s disease (PD).  CI patients have particular features. These are preliminary data of a 
cohort study of Moldovan patients with incident Parkinson’s disease.
Material and methods: 65 out of 111 consecutive PD patients (mean age 64.87 ± 7.69 y.o.; disease duration 50.21 ± 38.61 mo.; 48 women (43.2%), 63 
men (56.8%)) underwent Montreal Cognitive Assessment (MoCA) test. Cognitive status graded as: (1) normal and (2) impaired cognition. 
Results: There were similar: ages (65.79 ± 7.13 vs 62.17 ± 12.21 y.o.), onset ages (61.44 ± 7.61 vs 57.00 ± 12.95 years), disease duration (49.63 ± 36.78 vs 
66.00 ± 26.48) months), levodopa (574.58 ± 129 vs 249.55) and agonists doses (5.19 ± 3.02 vs 1.05 ± 0.05) and Beck scores (8.13 ± 6.21 vs 7.4 ± 3.85), in 
groups. CI was present in 59 (90.8%) patients; more frequent in patients with cardiovascular risk factors (91.7%, p> 0.05), symmetrical Parkinsonism 
(93.2%, p> 0.05), and in first disease symptom bradykinesia patients (93.8%, p> 0.05). Upper / Lower Asymmetry Index were lower in CI patients, all 
lower type patients (p> 0.05) having CI.  MoCA scores correlated with Unified Parkinson’s Disease Rating Scale in ON fase (UPDRSon), (r = -0.320, 
p <0.022), and red flags number (r = -0.590, p < 0.006).
Conclusions: Cognitive impairment is more expectable in akinetic, symmetric and lower type Parkinsonism, also in patients with cardiovascular risk 
factors, with probable PD, and a more motor impairment.
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frequently and more often have a disturbed pull test than 
PD patients with normal CT findings [6]. There is a strong 
association between the severity of age-related vascular 
changes as white matter lesions and the severity of gait and 
motor compromise, probably because white matter lesions 
may interfere with central processing of sensory-motor sig-
nals, leading to impaired gait and postural responses, and 
resulting in an increased frequency of falls [7]. 
Material and methods
These are preliminary data of a cohort study of Moldovan 
patients with incident Parkinson’s disease. Diagnosis of PD 
was based on widely acknowledged criteria [8]. Structured 
interview on complaints, medical history and family history 
of cardiovascular, neurological and psychiatric diseases and 
drug history was applied; general neurological and medical 
examinations were conducted. Severity of parkinsonism and 
disability were assessed by the Modified Unified Parkinson’s 
Disease Rating Scale (MDS-UPDRS) [9]. Cognitive impair-
ment was ascertained by Montreal Cognitive Assessment 
(MoCA) Scale [10]. Patients were subclassified at baseline 
into two groups according to MoCA scores: (1) normal cog-
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nition PD patients and (2) cognitively impaired (CI) PD 
patients. The data analysis was performed via statistical pro-
gram StatDirect, using descriptive, variation, and correla-
tional analysis. Student’s t tests or Mann-Whitney tests were 
used as appropriate. P values less than 0.05 were considered 
statistically significant. 
Results and discussion
The study comprised 111 consecutive PD patients. The 
mean age in the cohort was 64.87 ± 7.69 y.o. Patients had 
mean disease duration of 50.21 ± 38.61 months. Forty-eight 
patients (43.2%) were women and 63 patients (56.8%) were 
men. 
Sixty-five out of 111 patients underwent MoCA test. The 
Montreal Cognitive Assessment has adequate psychomet-
ric properties as a screening instrument for the detection 
of mild cognitive impairment or dementia in Parkinson’s 
disease, in particular for language fluency and visuospatial 
tests, that are more prevalent in PD [10]. According to their 
MoCA scores, our PD patients were divided in: (1) normal 
cognition (control group) and (2) cognitive impaired (CI) 
patients, with a cut-off of 26/30 [10]. 
Fifty-nine patients (90.8%) of the cognitively tested pa-
tients had a MoCA score below 26 and were assigned to the 
cognitive impaired (CI) group. 
Cognitive dysfunction is prevalent in PD. Approximately 
10% of a PD population develop dementia per year and the 
relative risk for developing dementia in PD compared to 
non-PD subjects ranges from 1.7 - 5.9 [11].  In Buter T.C. et 
al. study from a total of 233 PD patients, 140 patients (60%, 
95% CI 54% to 66%) had developed dementia by the end of 
the study period, but the cumulative incidence of dementia 
steadily increased with age and duration of PD to 80% - 90% 
by the age of 90 years; women lived with PD longer than 
men and spent more years with dementia [12]. 
The age of CI patients (65.79 ± 7.13 y.o.) in this study 
was slightly higher, but similar to those of normal cogni-
tion patients (62.17 ± 12.21 y.o., p>0.05). It is known that 
aging is a risk factor for mild cognitive impairment [11] and 
the strongest predictive factor of dementia in PD patients 
[11]. An argument of association of CI and age comes from 
a functional RMI study [13] which proves age-related re-
duction of hub function in the medial prefrontal cortex. The 
results of a study [11] provide, that having  mild CI, was 
associated with: older age at assessment, older age at disease 
onset, male gender, depression, more severe motor symp-
toms, and advanced disease stage.
In the present study PD onset ages (61.44 ± 7.61 vs 57.00 
± 12.95 years, p>0.05) and disease duration (49.63 ± 36.78 
vs 66.00 ± 26.48 months, p>0.05) in CI patients were similar 
to normal cognition patients.
Levodopa equivalent daily doses (574.58 ± 129 vs 249.55 
mg, p>0.05) and agonists doses (5.19 ± 3.02 vs 1.05 ± 0.05 
mg, p>0.05) were slightly higher, but without statistic differ-
ence between study and control group. Levodopa (L-dopa) 
is the gold standard treatment for Parkinson’s disease and 
the use of L-dopa in patients with Parkinsonism with de-
mentia does not adversely affect cognitive function. Molloy 
S.A. et al. also established in their study, that the mean daily 
dose of L-dopa was larger in patients with PD dementia 
(672 (451) mg) than in those with Parkinson’s disease (407 
(197) mg, p = 0.02) with normal cognition [14]. The expla-
nation may be more motor impairment associated with CI 
in PD.
The most common clinically relevant neuropsychi-
atric symptoms in PD are apathy (38.9%), depression 
(34.5%), and anxiety (23.8%) [15]. Depressive symptoms 
in Parkinson's disease correlate with impaired global and 
specific cognitive performance [16]. When screened for de-
pression, patients with CI of this study, had insignificantly 
higher Beck scores than patients without CI (8.13 ± 6.21 vs 
7.4 ± 3.85, p>0.05). As usual, depressive symptoms corre-
late with global cognitive performance, but naming, verbal 
memory, and language are the most susceptible affected 
cognitive domains [16].
The present research revealed that CI was more frequent 
in patients with cardiovascular risk factors (according to 
QRISK3 list [17]). So, 91.7% of patients having one or more 
vascular risk factors, had emphasized CI on MoCA test, vs 
80.0% of those not reporting vascular risk factors (p> 0.05). 
According to recent data, a third of all dementia cases may 
be preventable, due to cardiovascular risk factors, and  tri-
als targeting primarily cardiovascular risk factors show im-
proved cognitive function in people at risk [18].  In both 
sexes, 10-year absolute risk of all-cause dementia increases 
with increasing age, number of apolipoprotein E (APOE) e4 
alleles, number of genome-wide association studies (GWAS) 
risk alleles, and presence of cardiovascular risk factors [18].
 Forty-one of our patients (93.2%) with symmetrical 
Parkinsonism (according to their right/left asymmetry in-
dex) had CI (vs 18p (85.7%, p> 0.05). In patients report-
ing bradykinesia as the first disease symptom, 30 patients 
(93.8%) developed CI, in contrast to 23 patients (85.2%), 
reporting tremor as the first disease symptom (p> 0.05). 
Alves G. et al. found that in nearly all dementia cases, 
dementia was preceded by PIGD (postural instability gait 
disorder) or a kinetic dominant or by the transfer from 
tremor-dominant (TD) to PIGD type PD. The odds ratio for 
dementia was 56.7 (95% CI: 4.0-808.4; P = 0.003) for pa-
tients changing from TD or indeterminate subtype to PIGD 
subtype, and 80.0 (95% CI: 4.6-1400.1; P = 0.003) for pa-
tients with persistent PIGD subtype (compared to patients 
with persistent TD or indeterminate subtype). Patients with 
TD subtype at baseline become demented only when they 
developed PIGD subtype; dementia did not occur among 
patients with persistent TD subtype of Parkinsonism [19].
Upper / Lower Asymmetry Indexes (0.60 ± 0.37 vs 2.4 ± 
0.97, p> 0.05) were lower in CI patients indicating a relative 
symmetric involvement of limbs.
According to the “α-Synuclein Origin and Connectome 
Model of Parkinson’s Disease Motor Asymmetry”, “body-
first” patients at onset (initial origin of α-Synuclein pa-
thology in peripheral nervous system spreading bilateral 
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to brain) already have a larger, more symmetric burden of 
α-Synuclein pathology, which in turn promotes symmetric 
faster disease progression and accelerated cognitive decline 
[20].
In the current study, patients with predominant involve-
ment of lower limbs, according to their superior/inferior 
asymmetry index, were assigned as lower type Parkinsonism 
patients. All lower type Parkinsonism patients of this study 
(15 – 100%) developed CI, in contrast to control (18 – 
85.6%), p>0.05.
Estimates of the frequency of lower type Parkinsonism, 
indicating a vascular origin vary greatly worldwide: from 3% 
to 6% of all Parkinsonism cases [21]. Attention and memory 
impairment were found in 73.5% of patients with vascular 
Parkinsonism after mean disease duration of 4.4±3.4 years 
in Colosimo C. et al. study [22].
MoCA and Unified Parkinson’s Disease Rating Scale in 
ON fase (UPDRSon) scores in this study were inversely cor-
related – patients with more severe motor impairment had 
lower cognitive scores, hence more expressed cognitive im-
pairment (r = -0.320, p <0.022).
According to a recent study, female gender and education 
supported cognitive function in PD, while age and depres-
sion scores were inversely correlated with overall cognition; 
and UPDRS had little influence on cognition; the conclu-
sion of that study being that education, aging, comorbidity, 
and gender may impact cognition more than overall disease 
severity in PD [23]. However, another study on 2327 PD pa-
tients with a disease duration of over 20 years, found that 
demented PD patients exhibited more severe motor features 
compared to non-demented PD patients [24]. Memory im-
pairment was most common (13.3%; 11.6–15.3), followed 
by visuospatial (11.0%; 9.4–13.0) and attention/executive 
ability impairment (10.1%; 8.6–11.9); (11.3% 9.7–13.1) 
were classified as nonamnestic single-domain MCI, 8.9% 
(7.0–9.9) as amnestic single-domain, 4.8% (3.8–6.1) as am-
nestic multiple-domain, and 1.3% (0.9–2.1) as nonamnestic 
multiple-domain. MoCA scores are lower in PD, particu-
larly for language fluency and visuospatial tests [10].
There were recorded the presence and number of red 
flags, according to MDS clinical diagnostic criteria for 
Parkinson’s disease [25]. The number of red flags also cor-
related with MoCA scores. number (r = -0.590, p < 0.006), 
indicating that a lower degree of certainty of Parkinson’s dis-
ease diagnosis is associated with a more pronounced cogni-
tive deficit.
Conclusions
According to the presented data, patients with 
Parkinson’s disease and cognitive impairment, displayed no 
difference regarding ages, onset ages and disease duration 
compared to the controls.  Cognitive impairment was more 
prevalent in akinetic PD phenotype, as well as in symmetric 
and lower type Parkinsonism. Patients having cardiovascu-
lar risk factors more frequently had cognitive impairment 
as well; and cognitive dysfunction was associated with more 
pronounced motor impairment.
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